Search
Ceftiofur
go.drugbank.com/drugs/DB11485ExperimentalVet approvedIt is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product. … The metabolite desfurolyceftiofur also has antibiotic activity, consequently the two compounds are measured together to monitor for antibiotic activity in the milk.
Oleic Acid
go.drugbank.com/drugs/DB04224ApprovedInvestigationalVet approvedIt is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)
SNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication an...
Polidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalThe formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Lunacalcipol
go.drugbank.com/drugs/DB05024InvestigationalCytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalSurotomycin has a fourfold greater in vitro potency than vancomycin against C. … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection.
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Pidotimod
go.drugbank.com/drugs/DB11364InvestigationalPidotimod is a synthetic dipeptide with immunomodulatory properties.